Weekly Recap: ALIGN-ACS fast enrollment and 12—lead patch FDA progress

HeartBeam, Inc. (NASDAQ:BEAT) quickly completed ALIGN-ACS enrollment and will present results at TCT 2026 while HEADSTART-ACS advances and a pre-submission to the FDA targets a pivotal MI study; its 12—lead patch moves toward FDA clearance and the company is pursuing strategic partner commercial pl…